TICKERNERD
Menu
IRWDIRWDHealthcare · Drug Manufacturers - Specialty & Generic

IRWD Stock Forecast: Ironwood Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 24 Sept 2026
$4.19
−1.87% on the day

The 4 Wall Street analysts covering Ironwood Pharmaceuticals, Inc. hold a median 12-month price target of $5.35 — +27.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 100 of 100 as at 23 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$705.6M
Ticker Nerd rank
100 / 100
Median analyst target
$5.35
Analysts covering
4
Revenue$113.0M+32.6% y/y
Operating income$79.3M
Net income$51.3M
Free cash flow$58.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.9%
1M
+1.5%
YTD
+24.3%
1Y
+205.8%
From 52W high
−22.3%
From 52W low
+229.9%
$1.27
$5.39
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IRWD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Ironwood Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 23 Sept 2026
100 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
100
Quality
99
Growth
99
Momentum
93
Issuance
88
Accruals
87
Revisions
77
Size
49
Volatility
45

Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Volatility (45): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IRWD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IRWD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26IRWDHigh $10.00Median $5.35Low $3.70

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
2 Buy2 Hold0 Sell
Low $3.70Median $5.35High $10.00

The green dot is the last close — the median target sits +27.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
26 Feb 2026CitizensMaintainsMarket Outperform$8.00 → $10
5 Jan 2026CitizensUpgradeMarket Outperform—
5 Jan 2026Wells FargoMaintainsEqual-Weight—
11 Nov 2025Wells FargoMaintainsEqual-Weight—
15 Apr 2025JefferiesDowngradeHold—
15 Apr 2025Wells FargoDowngradeEqual-Weight—
14 Apr 2025Leerink PartnersMaintainsMarket Perform—
30 Jan 2025JMP SecuritiesMaintainsMarket Outperform—
22 Jan 2025Craig-HallumMaintainsBuy—
9 Sept 2024Leerink PartnersInitiatesMarket Perform—
9 Aug 2024Craig-HallumMaintainsBuy—
9 Aug 2024Wells FargoMaintainsOverweight—
10 May 2024Craig-HallumMaintainsBuy—
1 Mar 2024Wells FargoMaintainsOverweight—
16 Feb 2024Piper SandlerMaintainsOverweight—
17 Jan 2024Craig-HallumInitiatesBuy—
14 Dec 2023Wells FargoInitiatesOverweight—
28 Sept 2023JMP SecuritiesInitiatesMarket Outperform—
23 May 2023Piper SandlerMaintainsOverweight—
29 Aug 2022Piper SandlerInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IRWD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

IRWD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Sept 2026, Ironwood Pharmaceuticals, Inc. returned +205.8% against +17.3% for the S&P 500, dividends included.

IRWD vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250300350400Oct 25Jan 26Apr 26Jul 26IRWDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IRWD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+11.0%
Analysts raising
1
Analysts cutting
0
Fundamentals

Ironwood Pharmaceuticals, Inc. (IRWD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
5.4×

Cheaper than 65% of US stocks

Price / sales
1.8×

Cheaper than 54% of US stocks

Price / book
−4.3×

Cheaper than 96% of US stocks

EV / EBITDA
4.3×

Cheaper than 54% of US stocks

Growth & margins
Revenue growth (YoY)
32.6%

Higher than 79% of US stocks

Earnings growth (YoY)
117.3%

Higher than 86% of US stocks

Gross margin
—
Operating margin
70.2%

Higher than 99% of US stocks

Net margin
33.4%

Higher than 92% of US stocks

Returns & dividend
Return on equity
−9.2%

Higher than 36% of US stocks

Return on assets
47.0%

Higher than 99% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Ironwood Pharmaceuticals, Inc. (IRWD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Ironwood Pharmaceuticals, Inc. has a market value of $705.6M and an enterprise value of $1.0B.

  • Revenue in the twelve months to 30 June 2026: $389.3M. The latest quarter grew 32.6% year on year.

  • Net income over the same four quarters: $129.9M, a 33.4% net margin.

  • Diluted earnings per share, trailing twelve months: $0.77.

  • Free cash flow in the twelve months to 30 June 2026: $185.6M.

  • Shares outstanding: 165.2M.

  • Trailing P/E: 5.4×; forward P/E: 2.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Ironwood Pharmaceuticals, Inc. employs 100 people — $3.9M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 24 Sept 2026

Data provided by Twelve Data

Peers

IRWD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
IRWDIronwood Pharmaceuticals, Inc.$705.6M
100
COLLCollegium Pharmaceutical, Inc.$709.7M
74
GLASGlass House Brands, Inc.$650.0M
39
AQSTAquestive Therapeutics, Inc.$589.9M
54
TLRYTilray Brands, Inc.$559.8M
17
EOLSEvolus, Inc.$520.5M
91
KMDAKamada Ltd.$514.4M
96

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Ironwood Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IRWD news & analysis

Ironwood Pharmaceuticals (IRWD) is a Top-Ranked Momentum Stock: Should You Buy?

Zacks Investment Research · 21 Sept 2026positive

Zacks Investment Research highlighted Ironwood Pharmaceuticals as a top-ranked momentum stock, referencing its Style Scores feature from the Zacks Premium research service as a tool for identifying strong stocks. The piece focuses on the company's momentum among investors.

Why it matters — A favorable momentum ranking from a widely followed research service brings added attention to IRWD, which could interest current and prospective shareholders tracking the stock's performance.

5 Small Drug Stocks Poised to Benefit From a Biotech Recovery

Zacks Investment Research · 14 Sept 2026positive

Zacks Investment Research highlighted Ironwood Pharmaceuticals (IRWD) alongside INDV, RLMD, LRMR and CRDL as small drug stocks that could offer significant upside as biotech sentiment improves, citing catalysts and differentiated pipelines as supporting factors.

Why it matters — A favorable analyst mention of IRWD's pipeline and catalysts may raise visibility and investor interest in the company's prospects amid a recovering biotech sector.

Ironwood: Medicare Is Not The Problem I Thought It Was

Seeking Alpha · 11 Sept 2026positive

A Seeking Alpha article reassesses Medicare's impact on Ironwood Pharmaceuticals, concluding that Medicare pricing is less of a problem than previously thought. It reports that LINZESS pricing is close to Medicare's 2027 price, with the 44% sales increase mostly pricing-driven while underlying demand grew only 4% to 5%.

Why it matters — This reassessment of Medicare's pricing effect on LINZESS is significant for Ironwood watchers because Medicare's negotiated price was considered a key risk to the company's revenue outlook.

Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference

Business Wire · 3 Sept 2026neutral

Ironwood Pharmaceuticals announced that its management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10th at 10:15 a.m. ET. A live webcast and replay will be available through the company's website.

Why it matters — This event gives Ironwood investors and analysts an opportunity to hear directly from management and gain insight into the company's outlook during the conference.

Ironwood Pharmaceuticals: High Dependence On Its Next Trial

Seeking Alpha · 26 Aug 2026neutral

Ironwood Pharmaceuticals, a small-cap GI-focused biotech, raised its full-year LINZESS U.S. net sales guidance to $1.15–$1.2 billion and its own revenue forecast to $460–$485 million. Its pipeline asset apraglutide for SBS-IF showed statistically significant Phase 3 results, though LINZESS faces patent expiry by 2029–2030 and apraglutide's trial is key to future value.

Why it matters — A IRWD watcher would care because the company's near-term growth relies heavily on the forthcoming apraglutide trial as its LINZESS patent approaches expiry by 2029–2030.

FAQ

Frequently asked questions about IRWD stock

What is the IRWD stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Ironwood Pharmaceuticals, Inc. have a median 12-month price target of $5.35, with estimates ranging from $3.7 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IRWD stock a buy right now?

Of the 4 analysts covering Ironwood Pharmaceuticals, Inc., 2 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ironwood Pharmaceuticals, Inc. 100 out of 100 across roughly 4,600 US stocks as at 23 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IRWD?

As at 23 Sept 2026, Ironwood Pharmaceuticals, Inc. ranks 100 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).

Will IRWD stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +27.7% from the last close, and Ticker Nerd's factor model ranks Ironwood Pharmaceuticals, Inc. 100 out of 100 as at 23 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IRWD stock forecast for 2030?

No analyst covering Ironwood Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IRWD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.7 to $10 over the next 12 months.

How has IRWD stock performed over the past year?

Ironwood Pharmaceuticals, Inc. returned +205.8% over the 12 months to 24 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ironwood Pharmaceuticals, Inc. do?

Ironwood Pharmaceuticals, Inc. Class A Common Stock represents ownership in Ironwood Pharmaceuticals, Inc., a biotechnology company focused on developing and commercializing therapies for gastrointestinal disorders and rare diseases.

What is the latest news on IRWD?

The most recent item we track (Zacks Investment Research, 21 Sept 2026): "Ironwood Pharmaceuticals (IRWD) is a Top-Ranked Momentum Stock: Should You Buy?". Zacks Investment Research highlighted Ironwood Pharmaceuticals as a top-ranked momentum stock, referencing its Style Scores feature from the Zacks Premium research service as a tool for identifying strong stocks. The piece focuses on the company's momentum among investors.

Company

About Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc. Class A Common Stock represents ownership in Ironwood Pharmaceuticals, Inc., a biotechnology company focused on developing and commercializing therapies for gastrointestinal disorders and rare diseases. Its current business centers on human therapeutics, with an emphasis on medicines for conditions such as irritable bowel syndrome with constipation and chronic idiopathic constipation. The company’s commercial portfolio is anchored by LINZESS, a treatment used in gastrointestinal care, while its broader pipeline reflects ongoing work in GI-focused and other specialty medicine programs. Headquartered in Boston, Massachusetts, Ironwood serves patients, healthcare providers, and commercial partners through product development, marketing, and lifecycle management in the pharmaceutical sector. As a publicly traded healthcare company, it plays a role in the specialized drug market by addressing areas of significant unmet medical need.

CEO Mr. Thomas A. McCourt · 100 employees · United States · https://ironwoodpharma.com